Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Breakthrough COVID-19 Cases Raise Concern Over B.1.617 Variant

CEPI Offers Testing Against Variants Of Concern

Executive Summary

As the B.1.617 variant of SARS-CoV-2 spreads to countries including the UK and US after having caused havoc in India, vaccine effectiveness against this variant is under the lens with breakthrough cases reported post full vaccination. Meanwhile, CEPI’s offer to help in testing against variants has potential to harmonize assessment of COVID-19 vaccines performance.

You may also be interested in...



India’s COVID-19 Surge Forced Another Abrupt Stop Of US FDA In-Person Inspections

Agency inspectors worked in the country for about a month before the coronavirus infection surge forced another halt.

China Authorizes New Inactivated Vaccine Amid Doubt Over Sinopharm Jabs

A new emergency authorization marks China’s fourth approval for inactivated COVID-19 vaccines, despite lingering doubts over the protection offered by the technology and surging cases in one of the most vaccinated countries where Sinopharm’s inactivated vaccines are widely used.

UK Steps Up Search For Vaccines Against ‘Variants Of Concern’

As the World Health Organization brands the Indian virus a “variant of concern,” the UK is planning to use a lab-grown virus variant in challenge trials of current and new vaccines, and is also investing in new variant vaccine testing facilities. A new study will use Oxford Immunotec’s T cell test to monitor people’s immunological response to infection or vaccination.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC144388

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel